Programmed Cell Death Ligand 1 Expression in Cytological and Surgical Non-Small Cell Lung Cancer Specimens in Association with EGFR Mutation and Overall Survival: A Single-Institution Experience

Creative Commons License

SAYMAN GÖKAL E., Vardar Aker F., Kus Silav Z., Oven B. B.

TURKISH JOURNAL OF PATHOLOGY, cilt.38, sa.3, ss.261-274, 2022 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5146/tjpath.2022.01572
  • Dergi Adı: TURKISH JOURNAL OF PATHOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.261-274
  • Anahtar Kelimeler: Epidermal growth factor receptor, Non-small cell lung cancer, Programmed cell death ligand-1, Survival, TUMOR-INFILTRATING LYMPHOCYTES, PD-L1 EXPRESSION, CLINICAL-SIGNIFICANCE, NIVOLUMAB ANTI-PD-1, PROGNOSTIC-FACTOR, BMS-936558, ONO-4538, SAFETY, ADENOCARCINOMA, PEMBROLIZUMAB
  • İnönü Üniversitesi Adresli: Evet

Özet

Objective: The aim of this study was to evaluate programmed cell death ligand-1 (PD-L1) expression and the relationship between driver mutations and survival analysis in advanced-stage non-small cell lung carcinoma (NSCLC).